Axe falls at Digitas Health

Share this article:
David Kramer
David Kramer
Digitas Health today laid off 57 staff – around 8% of its 624-strong workforce – in the latest step of a structural reorganization designed to generate efficiencies and create shared resources with Publicis sibling Razorfish Health.

The majority of the cuts are thought to come from in-house production teams, much of whose work can be outsourced more efficiently across the Publicis network. Some employees have been transferred to the UK office.

Three weeks ago MM&M broke the news that Digitas Health and Razorfish Health would undergo a reorganization which would involve: the appointment of co-presidents Michael du Toit and Alexandra von Plato to run both brands; the creation of a global executive team, headed by David Kramer, CEO of both agencies; and the establishment of shared centers of excellence between the two.

While Kramer had originally said last month that no job cuts were imminent, he did add that “it is possible,” and therefore it comes as little surprise that this efficiency-led initiative has borne casualties.

Publicis acquired Digitas for $1.3 billion in 2006 and paid Microsoft $530 million for Razorfish in 2009. In May, the holding company announced it would buy another big digital network, Rosetta, for $575 million, leaving it as a standalone unit.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...